Thrombopoietin is synergistic with other cytokines for expansion of cord blood progenitor cells.
We investigated the effects of recombinant human thrombopoietin (TPO) in combination with various cytokines including erythropoietin (EPO), interleukin-3 (IL-3), interleukin-6 (IL-6), and stem cell factor (SCF) on megakaryopoiesis, and the expansion of CD34+CD41a+ cells from human cord blood CD34+ cells with these cytokines under serum-free conditions. Human cord blood CD34+ cells were cultured in Megacult (Stem Cell Technologies Inc. Vancouver, Canada) in the presence of recombinant growth factors. Colony-forming unit-megakaryocyte (CFU-M) colonies were counted on day 14. CD34+CD41a+ and CD34-CD41a+ cell expansion was analyzed using a serum-free liquid culture system for 7 days with recombinant growth factors. TPO alone had a concentration-dependent effect on megakaryocyte colony growth. At concentrations above 1 ng/ml, TPO supported significant CFU-Meg colony formation in a concentration-dependent manner. The combination of TPO plus other cytokines, including EPO, IL-3, and SCF, resulted in a synergistic enhancement of the number of CFU-Meg colonies, but IL-6 failed to enhance the effect of TPO. The number of CD41a+ cells increased after 7 days in liquid culture of human cord blood CD34+ cells with various cytokines (EPO, IL-3, IL-6, SCF) combined with TPO, but SCF plus TPO only resulted in a significant synergistic increment of CD34+CD41a+ cells compared with TPO alone. The results of the present study indicate that EPO, IL-3, and SCF can be synergistic with TPO to stimulate proliferation of CFU-Meg and suggest that SCF plus TPO can expand CD34+CD41a+ cells to effect the rapid recovery of platelets in patients following stem cell transplantation.
Won
J H
JH
Department of Internal Medicine and Institute for Clinical Molecular Biology Research, Soon Chun Hyang University College of Medicine, Seoul, Korea. jhwon@hosp.sch.ac.kr
Cho
S D
SD
Park
S K
SK
Lee
G T
GT
Baick
S H
SH
Suh
W S
WS
Hong
D S
DS
Park
H S
HS
D018952:Antigens, CD34 / Q000032:analysis; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D016895:Culture Media, Serum-Free; D016207:Cytokines / Q000494:pharmacology*; D004357:Drug Synergism; D005312:Fetal Blood / Q000166:cytology*; D005434:Flow Cytometry; D006410:Hematopoiesis / Q000187:drug effects / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008533:Megakaryocytes / Q000166:cytology / Q000276:immunology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D011994:Recombinant Proteins / Q000494:pharmacology; D013926:Thrombopoietin / Q000494:pharmacology*
D018952:Antigens, CD34; D016895:Culture Media, Serum-Free; D016207:Cytokines; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D013926:Thrombopoietin